Immuno-Oncology Biomarker Measurement With High Sensitivity And Speed Using SimpleStep ELISA® Kits And SPECTROstar® ^Nano

By Mallori Milligan, Abcam, Scott Detmer, Abcam, and Carl Peters, BMG LABTECH

This content is brought to you by Abcam, a Danaher Operating Company.

In the clinic, cancer therapies leveraging patients' immune responses have demonstrated promising results. However, a significant unmet need remains as many patients either develop resistance to the drugs or do not respond to them, highlighting a persistent need for more effective solutions. Advancing treatment options requires a deeper understanding of how cancers evade the immune system and the identification of biomarkers that can predict clinical outcomes or indicate target engagement. These insights have the potential to personalize therapies and improve treatment strategies.

Explore results demonstrating the successful use of SimpleStep ELISA® kits to detect three key biomarkers: Programmed Death Ligand 1 (PD-L1), Interleukin-8 (IL-8), and Interferon Gamma (IFN-γ). Treatments aimed at the Programmed Death 1 (PD-1) / PD-L1 pathway have yielded promising results, as this pathway plays a crucial role as an immune checkpoint. Additionally, the expression of PD-L1 in tumors and, in some cases, in immune cells, has been linked to the successful blocking of this pathway. Both IL-8 and IFN-γ3 expression levels have also been observed to change in response to treatments targeting the PD-1/PD-L1 pathway.